This strategy utilized DMA to inhibit cellular Ca2+ influx into tumor cells, reducing exosomal release, while ROSCO downregulated PD-L1 expression in both tumor cells and exosomes and disrupted the feedback loop between PD-L1 upregulation and interferon-γ signaling. The gene discussed is CD274; the disease is neoplasm.